DelveInsight's "Sudden Sensorineural hearing loss (SSNHL)—Market-2028" report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Sudden Sensorineural hearing loss in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Sudden Sensorineural hearing loss from 2017 to 2028 segmented by seven major markets.
Sudden Sensorineural hearing loss (SNHL) is the most common type of hearing loss, referred colloquially as “nerve hearing loss”, which indicates abnormal functioning of the cochlea, auditory nerve, or higher aspects of central auditory perception or processing. Sudden Sensorineural hearing loss (SSNHL) is a subset of SHL that is sensorineural in nature, occurs within a 72-h window, and meets certain audiometric criteria. In major parts of the world, Sudden Sensorineural hearing loss (SSNHL) is most often defined as “Sensorineural hearing loss of 30 dB or greater over at least three contiguous audiometric frequencies occurring over 72 h”. In 2012, The Research Committee of the Ministry of Health and Welfare for Acute Profound Deafness in Japan also accepted this definition.
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
SSNHL can be categorized into congenital and acquired sensorineural hearing loss. Congenital sensorineural hearing loss happens during pregnancy, some causes include prematurity, maternal diabetes, lack of oxygen during birth, genetics, and others. Whereas acquired sensorineural hearing loss occurs after birth and is speculative and probably multifactorial, but various etiological theories have been proposed. Infection, vascular impairment, autoimmune disorders, trauma, inner ear anomaly, central nervous system (CNS) disease have all been implicated, but in many patients, no obvious cause is found (idiopathic). Cardiovascular disease, cigarette smoking, and hypertension appear to be the most common risk factors associated with SSNHL. Advanced age, severe hearing loss, heredity, audiogram shape, and presence of vertigo are significant negative prognostic indicators for untreated SSNHL.
For the diagnosis of the SSNHL, it is important to distinguish between conductive hearing loss and sensorineural hearing loss. The diagnosis of congenital hearing loss starts with a newborn hearing screening. A thorough history and a careful physical examination are essential to the diagnosis and treatment of hearing loss. Weber's test is performed by softly striking a 512-Hz tuning fork and placing it midline on the patient's scalp, or on the forehead, nasal bones, or teeth. If the hearing loss is conductive, the sound will be heard best in the affected ear. If the loss is sensorineural, the sound will be heard best in the normal ear. The sound remains midline in patients with normal hearing.
The Sudden Sensorineural hearing loss epidemiology division provides insights about historical and current incident pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident cases of SSNHL, Gender-Specific cases of SSNHL, Age-Specific cases of SSNHL, Severity Specific cases of SSNHL, and Nature Specific cases of SSNHL) scenario of Sudden Sensorineural Hearing loss in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.
According to DelveInsight, the total Incident cases of Sudden Sensorineural hearing loss (SSNHL) in the 7MM was found to be 331,961 in 2017. The incidence of Sudden Sensorineural hearing loss in the 7MM is expected to increase during the study period of 2017-2028.
This segment of the Sudden Sensorineural hearing loss report encloses the detailed analysis of late-stage (Phase-III and Phase-II) pipeline drugs and other potential drug candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Sudden Sensorineural hearing loss (SNHL) is commonly encountered in audiology and otolaryngologic practice. Several agents have been explored for the treatment of idiopathic SNHL, including corticosteroids, anti-inflammatory agents, antimicrobials, calcium antagonists, vitamins, essential minerals, vasodilators, volume expanders, defibrinogenators, diuretics, and hyperbaric oxygen. SNHL may be managed with hearing aids, when hearing aids are not enough, this type of hearing loss can be surgically treated with cochlear implants.
Detailed chapters of emerging therapies, such as Sonsuvi (AM-111) (Auris Medical), STR001 (Strekin AG), SENS-401 (Sensorion), FX-322 (Frequency Therapeutics), and also details about some potential therapies such as Valganciclovir (Genentech), LY3056480 (Audion Therapeutics), and Anakinra (Swedish Orphan Biovitrum), others have also been provided in the report.
The Sudden Sensorineural hearing loss market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
According to DelveInsight, the market for Sudden Sensorineural hearing loss in 7MM was found to be approximately USD 110.91 Million in 2017.
Sudden Sensorineural hearing loss market size in EU-5 accounted for 45% of the total market in 2017. The EU-5 led the market in 2017, followed by the United States and Japan, respectively. Due to the high incidence of this disease in the region, the Sudden Sensorineural hearing loss treatment market in the EU-5 is expected to dominate the market during the forecast period (2019-2028).
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.
The dynamics of Sudden Sensorineural hearing loss market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as Sonsuvi (AM-111) (Auris Medical), STR001 (Strekin AG), SENS-401 (Sensorion), FX-322 (Frequency Therapeutics), and others in the Sudden Sensorineural hearing loss market by 2028.
• Incident cases of Sudden Sensorineural hearing loss
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
• 10-Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Sudden Sensorineural hearing loss market
• Organize sales and marketing efforts by identifying the best opportunities for Sudden Sensorineural hearing loss market
• To understand the future market competition in the Sudden Sensorineural hearing loss market
1. Key Insights
2. Sudden Sensorineural hearing loss (SSNHL): Market Overview at a Glance
2.1. Market Share (%) Distribution of SSNHL in 2017
2.2. Market Share (%) Distribution of SSNHL in 2028
3. Disease Overview: Sensorineural hearing loss (SNHL)
3.1. Introduction
3.2. Signs and Symptoms
3.3. Etiology
3.4. Pathophysiology
3.5. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Incident Cases of Sudden Sensorineural hearing loss
4.3. Country Wise-Epidemiology of Sensorineural hearing loss
4.4. United States
4.4.1. Assumptions and Rationale
4.4.2. Total Incident cases of SSNHL in the United States
4.4.3. Gender-Specific cases of SSNHL in the United States
4.4.4. Age-Specific Cases of SSNHL in the United States
4.4.5. Severity Specific cases of SSNHL in the United States
4.4.6. Nature Specific cases of SSNHL in the United States
4.5. EU5
4.5.1. Assumptions and Rationale
4.6. Germany
4.6.1. Total Incident cases of SSNHL in Germany
4.6.2. Gender-Specific cases of SSNHL in Germany
4.6.3. Age-Specific Cases of SSNHL in Germany
4.6.4. Severity Specific cases of SSNHL in Germany
4.6.5. Nature Specific cases of SSNHL in Germany
4.7. France
4.7.1. Total Incident cases of SSNHL in France
4.7.2. Gender-Specific cases of SSNHL in France
4.7.3. Age-Specific Cases of SSNHL in France
4.7.4. Severity Specific cases of SSNHL in France
4.7.5. Nature Specific cases of SSNHL in France
4.8. Italy
4.8.1. Total Incident cases of SSNHL in Italy
4.8.2. Gender-Specific cases of SSNHL in Italy
4.8.3. Age-Specific Cases of SSNHL in Italy
4.8.4. Severity Specific cases of SSNHL in Italy
4.8.5. Nature Specific cases of SSNHL in Italy
4.9. Spain
4.9.1. Total Incident cases of SSNHL in Spain
4.9.2. Gender-Specific cases of SSNHL in Spain
4.9.3. Age-Specific Cases of SSNHL in Spain
4.9.4. Severity Specific cases of SSNHL in Spain
4.9.5. Nature Specific cases of SSNHL in Spain
4.10. United Kingdom
4.10.1. Total Incident cases of SSNHL in the UK
4.10.2. Gender-Specific cases of SSNHL in the UK
4.10.3. Age-Specific Cases of SSNHL in the UK
4.10.4. Severity Specific cases of SSNHL in the UK
4.10.5. Nature Specific cases of SSNHL in the UK
4.11. Japan
4.11.1. Assumptions and Rationale
4.11.2. Total Incident cases of SSNHL in Japan
4.11.3. Gender-Specific cases of SSNHL in Japan
4.11.4. Age-Specific Cases of SSNHL in Japan
4.11.5. Severity Specific cases of SSNHL in Japan
4.11.6. Nature Specific cases of SSNHL in Japan
5. Current Treatment Practices
5.1. Clinical Practice Guideline: Sudden Hearing Loss
6. Unmet Needs
7. Emerging Therapies
7.1. Key cross competition- Emerging Therapies
7.2. AM-111: Auris Medical
7.2.1. Drug Description
7.2.2. Other Developmental Activities
7.2.3. Clinical Development
7.2.4. Safety and Efficacy
7.2.5. Product Profile
7.3. STR001: Strekin AG
7.3.1. Drug Description
7.3.2. Other Developmental Activities
7.3.3. Clinical Development
7.3.4. Safety and Efficacy
7.3.5. Product Profile
7.4. SENS-401: Sensorion
7.4.1. Drug Description
7.4.2. Other Developmental Activities
7.4.3. Clinical Development
7.4.4. Safety and Efficacy
7.4.5. Product Profile
7.5. FX-322: Frequency Therapeutics
7.5.1. Drug Description
7.5.2. Other Developmental Activities
7.5.3. Clinical Development
7.5.4. Safety and Efficacy
7.5.5. Product Profile
8. Other potential therapies
8.1. Valganciclovir: Genentech
8.1.1. Drug Description
8.1.2. Other Developmental Activities
8.1.3. Clinical Development
8.1.4. Safety and Efficacy
8.1.5. Product Profile
8.2. LY3056480: Audion Therapeutics
8.2.1. Drug Description
8.2.2. Other Developmental Activities
8.2.3. Clinical Development
8.2.4. Safety and Efficacy
8.2.5. Product Profile
8.3. Anakinra: Swedish Orphan Biovitrum (Sobi)
8.3.1. Drug Description
8.3.2. Other Developmental Activities
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
9. Sudden Sensorineural hearing loss: 7 Major Market Analysis
9.1. Key Findings
9.2. Market Size of Sudden Sensorineural hearing loss in 7MM
10. Market Outlook by Country
11. United States: Market Outlook
11.1. United States Market Size
11.1.1. Total Market Size of Sudden Sensorineural hearing loss
11.1.2. Market Size of Sudden Sensorineural hearing loss (SSNHL) by Therapies
12. EU-5 Countries: Market Outlook
12.1. Germany
12.1.1. Total Market size of Sudden Sensorineural hearing loss
12.1.2. Market Size of Sudden Sensorineural hearing loss (SSNHL) by Therapies
12.2. France
12.2.1. Total Market Size of Sudden Sensorineural hearing loss
12.2.2. Market Size of Sudden Sensorineural hearing loss (SSNHL) by Therapies
12.3. Italy
12.3.1. Total Market Size of Sudden Sensorineural hearing loss
12.3.2. Market Size of Sudden Sensorineural hearing loss (SSNHL) by Therapies
12.4. Spain
12.4.1. Total Market Size of Sudden Sensorineural hearing loss
12.4.2. Market Size of Sudden Sensorineural hearing loss (SSNHL) by Therapies
12.5. United Kingdom
12.5.1. Total Market Size of Sudden Sensorineural hearing loss
12.5.2. Market Size of Sensorineural hearing loss (SSNHL) by Therapies
12.6. Japan: Market Outlook
12.6.1. Total Market Size of Sudden Sensorineural hearing loss
12.6.2. Market Size of Sudden Sensorineural hearing loss (SSNHL) by Therapies
13. Market Drivers
14. Market Barriers
15. Appendix
15.1. Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight
Table 1: Identifiable Causes of Sudden Sensorineural Hearing Loss
Table 2: The main autoimmune target antigens in the inner ear
Table 3: Incident Cases of Sensorineural hearing loss in 7MM (2017-2028)
Table 4: Total Incident Cases of SSNHL in the United States (2017-2028)
Table 5: Gender-Specific Incident Cases of SSNHL in the United States (2017-2028)
Table 6: Age-Specific Cases of SSNHL in the United States (2017-2028)
Table 7: Severity Specific Cases of SSNHL in the United States (2017-2028)
Table 8: Nature Specific Cases of SSNHL in the United States (2017-2028)
Table 9: Total Incident Cases of SSNHL in Germany (2017-2028)
Table 10: Gender-Specific Cases of SSNHL in Germany (2017-2028)
Table 11: Age-Specific Cases of SSNHL in Germany (2017-2028)
Table 12: Severity Specific Cases of SSNHL in Germany (2017-2028)
Table 13: Nature Specific Cases of SSNHL in Germany (2017-2028)
Table 14: Total Incident Cases of SSNHL in France (2017-2028)
Table 15: Gender-Specific Cases of SSNHL in France (2017-2028)
Table 16: Age-Specific Cases of SSNHL in France (2017-2028)
Table 17: Severity Specific Cases of SSNHL in France (2017-2028)
Table 18: Nature Specific Cases of SSNHL in France (2017-2028)
Table 19: Total Incident Cases of SSNHL in Italy (2017-2028)
Table 20: Gender-Specific Cases of SSNHL in Italy (2017-2028)
Table 21: Age-Specific Cases of SSNHL in Italy (2017-2028)
Table 22: Severity Specific Cases of SSNHL in Italy (2017-2028)
Table 23: Nature Specific Cases of SSNHL in Italy (2017-2028)
Table 24: Total Incident Cases of SSNHL in Spain (2017-2028)
Table 25: Gender-Specific Cases of SSNHL in Spain (2017-2028)
Table 26: Age-Specific Cases of SSNHL in Spain (2017-2028)
Table 27: Severity Specific Cases of SSNHL in Spain (2017-2028)
Table 28: Nature Specific Cases of SSNHL in Spain (2017-2028)
Table 29: Total Incident Cases of SSNHL in the UK (2017-2028)
Table 30: Gender-Specific Cases of SSNHL in the UK (2017-2028)
Table 31: Age-Specific Cases of SSNHL in the UK (2017-2028)
Table 32: Severity Specific Cases of SSNHL in the UK (2017-2028)
Table 33: Nature Specific Cases of SSNHL in the UK (2017-2028)
Table 34: Total Incident Cases of SSNHL in Japan (2017-2028)
Table 35: Gender-Specific Incident Cases of SSNHL in Japan (2017-2028)
Table 36: Age-Specific Cases of SSNHL in the US (2017-2028)
Table 37: Severity Specific Cases of SSNHL in Japan (2017-2028)
Table 38: Nature Specific Cases of SSNHL in Japan (2017-2028)
Table 39: Strength of Action Terms in Guideline Statements and Implied Levels of Obligation
Table 40: Summary of Guideline Key Action Statements
Table 41: General Guidelines for Corticosteroid Therapy for SSNHL
Table 42: Key cross competition- Emerging therapies
Table 43: Key cross competition- Other potential therapies
Table 44: AM-111, Clinical Trial Description, 2019
Table 45: STR001, Clinical Trial Description, 2019
Table 46: SENS-401, Clinical Trial Description, 2019
Table 47: FX-322, Clinical Trial Description, 2019
Table 48: Valganciclovir, Clinical Trial Description, 2019
Table 49: AM-111, Clinical Trial Description, 2019
Table 50: Anakinra, Clinical Trial Description, 2019
Table 51: 7MM Size of SSNHL in USD Million (2017-2028)
Table 52: United States Market Size of SSNHL in USD Million (2017-2028)
Table 53: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Table 54: Germany Market Size of SSNHL in USD Million (2017-2028)
Table 55: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Table 56: France Market Size of SSNHL in USD Million (2017-2028)
Table 57: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Table 58: Italy Market Size of SSNHL in USD Million (2017-2028)
Table 59: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Table 60: Spain Market Size of SSNHL in USD Million (2017-2028)
Table 61: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Table 62: United Kingdom Market Size of SSNHL in USD Million (2017-2028)
Table 63: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Table 64: Japan Market Size of SSNHL in USD Million (2017-2028)
Table 65:Market Size of SSNHL by Therapies in USD Million (2017-2028)
Figure 1: Signs and Symptoms of Sensorineural hearing loss
Figure 2: The distribution of immune cells in the inner ear when the immune response is initiated
Figure 3: The mechanisms of inner ear damage by the type II-IV allergic reactions
Figure 4: WHO grading
Figure 5: Incident Cases of Sensorineural hearing loss in 7MM (2017-2028)
Figure 6: Total Incident Cases of SSNHL in the United States (2017-2028)
Figure 7: Gender-Specific Cases of SSNHL in the United States (2017-2028)
Figure 8: Age-Specific Cases of SSNHL in the United States (2017-2028)
Figure 9: Severity Specific Cases of SSNHL in the United States (2017-2028)
Figure 10: Nature Specific Cases of SSNHL in the United States (2017-2028)
Figure 11: Total Incident Cases of SSNHL in Germany (2017-2028)
Figure 12: Gender-Specific Cases of SSNHL in Germany (2017-2028)
Figure 13: Age-Specific Cases of SSNHL in Germany (2017-2028)
Figure 14: Severity Specific Cases of SSNHL in Germany (2017-2028)
Figure 15: Nature Specific Cases of SSNHL in Germany (2017-2028)
Figure 16: Total Incident Cases of SSNHL in France (2017-2028)
Figure 17: Gender-Specific Cases of SSNHL in France (2017-2028)
Figure 18: Age-Specific Cases of SSNHL in France (2017-2028)
Figure 19: Severity Specific Cases of SSNHL in France (2017-2028)
Figure 20: Nature Specific Cases of SSNHL in France (2017-2028)
Figure 21: Total Incident Cases of SSNHL in Italy (2017-2028)
Figure 22: Gender-Specific Cases of SSNHL in Italy (2017-2028)
Figure 23: Age-Specific Cases of SSNHL in Italy (2017-2028)
Figure 24: Severity Specific Cases of SSNHL in Italy (2017-2028)
Figure 25: Nature Specific Cases of SSNHL in Italy (2017-2028)
Figure 26: Total Incident Cases of SSNHL in Spain (2017-2028)
Figure 27: Gender-Specific Cases of SSNHL in Spain (2017-2028)
Figure 28: Age-Specific Cases of SSNHL in Spain (2017-2028)
Figure 29: Severity Specific Cases of SSNHL in Spain (2017-2028)
Figure 30: Nature Specific Cases of SSNHL in Spain (2017-2028)
Figure 31: Total Incident Cases of SSNHL in the UK (2017-2028)
Figure 32: Gender-Specific Cases of SSNHL in the UK (2017-2028)
Figure 33: Age-Specific Cases of SSNHL in the UK (2017-2028)
Figure 34: Severity Specific Cases of SSNHL in the UK (2017-2028)
Figure 35: Nature Specific Cases of SSNHL in the UK (2017-2028)
Figure 36: Total Incident Cases of SSNHL in Japan (2017-2028)
Figure 37: Gender-Specific Cases of SSNHL in Japan (2017-2028)
Figure 38: Age-Specific Cases of SSNHL in Japan (2017-2028)
Figure 39: Severity Specific Cases of SSNHL in Japan (2017-2028)
Figure 40: Nature Specific Cases of SSNHL in Japan (2017-2028)
Figure 41: Treatment Algorithm of Sensorineural hearing loss
Figure 42: Unmet Needs
Figure 43: 7 MM Size of SSNHL in USD Million (2017-2028)
Figure 44: Market Size of SSNHL in the US, USD Millions (2017-2028)
Figure 45: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Figure 46: Market Size of SSNHL in Germany, USD Millions (2017-2028)
Figure 47: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Figure 48: Market Size of SSNHL in France USD Millions (2017-2028)
Figure 49: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Figure 50: Market Size of SSNHL in Italy, USD Millions (2017-2028)
Figure 51: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Figure 52: Market Size of SSNHL in Spain, USD Millions (2017-2028)
Figure 53: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Figure 54: Market Size of SSNHL in the United Kingdom, USD Millions (2017-2028)
Figure 55: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Figure 56: Market Size of SSNHL in Japan, USD Millions (2017-2028)
Figure 57: Market Size of SSNHL by Therapies in USD Million (2017-2028)
Figure 58:Market Drivers
Figure 59:Market Barriers
